AxoGen Inc
NASDAQ:AXGN

Watchlist Manager
AxoGen Inc Logo
AxoGen Inc
NASDAQ:AXGN
Watchlist
Price: 18.99 USD 1.01% Market Closed
Market Cap: 842m USD

AxoGen Inc
Investor Relations

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 428 full-time employees. Its platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Avive Soft Tissue Membrane and Axotouch Two-Point Discriminator. Its products are used by surgeons during surgical interventions to repair a variety of physical nerve damage or transection throughout the body, which ranges from a simple laceration of a finger to a complex brachial plexus injury, as well as nerve injuries caused by dental, orthopedic, and other surgical procedures. Its Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Its portfolio of products is available in the United States, Canada, Germany, Spain, South Korea, and several other countries.

Show more
Loading

Earnings Calls

2024 Q4
Mar 6, 2025
Show Transcript
Previous
Next
Funko reports slight growth amid challenging tariffs and consumer sentiment.
2024 Q4
Mar 6, 2025

In Q4 2024, Funko achieved net sales of $294 million, up 1% year-over-year, primarily due to a 20% increase in direct-to-consumer sales, which now represent 29% of total sales. The company anticipates full-year 2025 net sales between $1.05 billion and $1.102 billion but expects adjusted EBITDA to be slightly lower at $80-$100 million. Despite headwinds from 20% tariffs and softening U.S. consumer behavior, Funko remains optimistic for Q2 2025 growth, driven by improved inventory management and strategic direct-to-consumer initiatives. The brand is particularly excited about expanded sports partnerships and global sales momentum, with notable performances across the EMEA region.

Show Full Analysis

Management

Mr. Nir Naor C.F.A., CPA, L.L.M., M.B.A.
Chief Financial Officer
No Bio Available
Ms. Karen Zaderej
Advisor
No Bio Available
Mr. Erick DeVinney
Chief Innovation Officer
No Bio Available
Mr. Todd Puckett
Vice President of Operations
No Bio Available
Mr. Harold D. Tamayo
Vice President of Finance & Investor Relations
No Bio Available
Mr. Marc A. Began
Executive VP, General Counsel & Chief Compliance Officer
No Bio Available
Ms. Doris Quackenbush
Vice President of Sales
No Bio Available
Mr. Jens Schroeder Kemp
Chief Marketing Officer
No Bio Available
Dr. Ivica Ducic M.D., Ph.D.
Chief Medical Officer
No Bio Available

Contacts

Address
FLORIDA
Alachua
13631 Progress Blvd Ste 400
Contacts
+13864626817.0
www.axogeninc.com